# OnCo record aldoxorubicin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/aldoxorubicin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "aldoxorubicin" ;
  schema:name "Aldoxorubicin"@en ;
  schema:alternateName "INNO-206"@en, "DOXO-EMCH"@en, "Aldox"@en ;
  schema:description "Aldoxorubicin is doxorubicin, the workhorse chemotherapy nicknamed the red devil, attached to a linker that hitches it to the body's own albumin so more reaches the tumour and less reaches the heart; it beat doxorubicin in a randomised phase 2 sarcoma trial but missed the primary endpoint of its phase 3, and a new company is now trying to finish its development."@en ;
  schema:url <https://onco.cc/drugs/aldoxorubicin/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Aldoxorubicin> ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2015.3101>, <https://clinicaltrials.gov/study/NCT02049905>, <https://www.geminithera.com/aldoxorubicin.html>, <https://doi.org/10.1200/JCO.2026.44.16_suppl.11565> ;
  onco:status "phase-3" ;
  onco:tag "gap-fill", "owner-request" ;
  onco:modality "Albumin-binding small-molecule prodrug of doxorubicin, intravenous" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/osteosarcoma/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/top2a/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/> ;
  onco:companies <https://onco.cc/companies/gemini-therapeutics/>, <https://onco.cc/companies/immunitybio/> ;
  onco:trials <https://onco.cc/trials/aldoxorubicin-phase-3-sts/>, <https://onco.cc/trials/nct04390399/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chawla-jama-oncol/> .